Coxibs: Evolving role in pain management

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 3 SUPPL. 1, 2002, Pages 15-24

  Katz, Nathaniel ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Analgesia; Arthritis; COX 2; Coxibs; NSAIDs; Pain

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CODEINE; DICLOFENAC; HYDROCODONE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; VALDECOXIB;

ALGORITHM; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DELIRIUM; DENTAL SURGERY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LOW BACK PAIN; NAUSEA; ORTHOPEDIC SURGERY; OSTEOARTHRITIS; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; SWEATING; VOMITING;

EID: 0036940471     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.37218     Document Type: Review

References (66)

1. Ashburn MA, Staats PS. Management of chronic pain. Lancet 1999:353:1865-9.
2. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: A review of the literature. Pain 1998;77:231-9.
3. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet 1999;354:1248-52.
4. Schnitzer T, Hochberg MC. COX-2 selective inhibitors in the treatment of arthritis. Cleve Clin J Med 2002;69:SI-20-SI-30.
5. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology 2001;120:594-606.
6. Hochberg TSM. COX-2 selective inhibitors in the treatment of arthritis. Cleve Clin J Med 2002;69:SI20-SI30.
7. Borenstein DG. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr Opin Rheumatol 2001;13:128-34.
8. Frank AO, De Souza LH. Conservative management of low back pain. Int J Clin Pract 2001;55:21-31.
9. Cassidy JD, Carroll LJ, Cote P. The Saskatchewan health and back pain survey. The prevalence of low back pain and related disability in Saskatchewan adults. Spine 1998;23:1860-6.
10. Katz N, Johnson K, Krupa D. Rofecoxib in the treatment of chronic low back pain in two multicenter trials. Spine 2002. In Press.
11. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-700.
12. Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag 2000;9:8-15.
13. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996;335:1124-32.
14. Dionne CE. Low back pain. In Epidemiology of Pain, Crombie IK (ed). Seattle, IASP Press; 1999.
15. Portenoy RK. Current pharmacotherapy of chronic pain. J Pain Symptom Manage 2000;19:S16-20.
16. McQuay H. Opioids in pain management. Lancet 1999;353:2229-32.
17. Dahl V, Raeder JC. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand 2000;44:1191-203.
18. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis & Rheumatism 2002;46:328-46.
19. Power I, Barratt S. Analgesic agents for the postoperative period. Nonopioids. Surg Clin North Am 1999;79:275-95.
20. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000;43:378-85.
21. Breivik EK, Barkvoll P, Skovlund E. Combining diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: A randomized, double-blind single-dose study. Clin Pharmacol Ther 1999;66:625-35.
22. Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, Park BK. Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A 2000;97:12741-5.
23. Salgia AD, Kosnik SD. When acetaminophen use becomes toxic. Treating acute accidental and intentional overdose. Postgrad Med 1999;105:81-4, 7, 90.
24. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
25. Katz WA. Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. Curr Opin Rheumatol 2002;14:63-71.
26. Katz WA. Approach to the management of nonmalignant pain. Am J Med 1996:101:54S-63S.
27. American Geriatric Society. The management of chronic pain in older persons: AGS panel on chronic pain in older persons. J Am Geriatr Soc 1998;46:635-51.
28. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2 p following 8.
29. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89:3-9.
30. Silverstein F, Simon L, on behalf of the CLASS Investigators. Celecoxib is associated with a lower incidence of serious GI toxicity relative to nonsteroidal anti-inflammatory drugs (NSAIDs) - The Celecoxib Long-term Arthritis Safety Study (CLASS) [abstract 1907]. Arthritis Rheum 2000;43(9 Suppl):S384.
31. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110:28S-32S.
32. Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002;94:55-9.
33. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
34. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
35. Celebrex (Celecoxib). US Prescribing Information. Pharmacia Corp, Peapack, NJ, 2000.
36. Vioxx (rofecoxib). US Product Information. Merck & Co, Whitehouse Station, NJ, 2000.
37. Goldman M, Schutzer S. Valdecoxib. Formulary 2002;37:68-77.
38. Bombardier C, Laine L, Reicin AS, Shapiro DR, Sperling RS. Risk factors for clinically important upper GI events: The VIGOR study. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic.
39. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
40. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
41. Geba GP, Pollis AB, Dixon ME, Dobbins TW, Rush JE, Weir MR. Comparative blood pressure effects of Rofecoxib, Celecoxib, and placebo in patients with osteoarthritis (OA): A randomized controlled trial. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic. Abstract SAT0095.
42. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000;91:1221-5.
43. Reuben SS, Fingeroth R, Krashell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002;17:26-31.
44. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: A randomized, controlled trial. Clin Ther 1999;21:943-53.
45. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-47.
46. Morrison BW, Fricke J, Brown J, Yuan W, Kotey P, Mehlisch DR. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials. JAMA 2000;131:1729-37.
47. Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo-and active comparator-controlled clinical trial. Clin Ther 2001;23:1446-55.
48. Chang DJ, Desjardins PJ, Chen E, Polis AB, McAvoy M, Mockoviak S, et al. Analgesic Efficacy of Rofecoxib Compares with Diclofenac for the Treatment of Acute Pain: A Randomized Controlled Trial. Paper presented at: American Pain Society; 2002.
49. Morrison B, Daniels S, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial. Obstet Gynecol 1999;94:504-8.
50. Gimbel JS, Brugger A, Zhao W, Verburg KM, Geis GS. Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther 2001;23:228-41.
51. McQuay HJ. Pre-emptive analgesia: A systematic review of clinical studies. Ann Med 1995;27:249-56.
52. Dimar JR 2nd, Ante WA, Zhang YP, Glassman SD. The effects of nonsteroidal anti-inflammatory drugs on posterior spinal fusions in the rat. Spine 1996;21:1870-6.
53. Martin GJ Jr. Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine 1999;24:2188-93.
54. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine 1998;23:834-8.
55. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br 2000;82:655-8.
56. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-8S.
57. Wolfe F, Kong SX, Watson DJ. Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol 2000;27:1373-8.
58. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
59. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
60. Singh G, Goldstein J, Fort J, Bello A, Boots S. Success-I in osteoarthritis: Celecoxib demonstrates similar efficacy to the conventional NSAIDs, diclofenac and naproxen, in patients with osteoarthritis treated in 39 countries in 6 continents [abstract SAT0093]. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic.
61. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999;21:1688-702.
62. Katz N, Johnson K, Krupa D, WD J, Borenstein D. Rofecoxib in the treatment of chronic low back pain in two multicenter trials. Paper presented at: 20th Annual Meeting of the American Pain Society; April 19-22, 2001; Phoenix, AZ. Abstract 718.
63. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-6.
64. World Health Organization. Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee (Technical Report Series 804). Geneva: World Health Organization; 1990.
65. Jenkins CA, Bruera E. Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients. Palliat Med 1999;13:183-96.
66. McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Oncol Rep 2000;2:351-7.